Phase 3 Prostate Cancer Trial, Recruiting NCT05448547 Sponsor: Sven Löffeler Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT05448547
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 75 years of age or older at the time of signing the consent form
  • People who are considered healthy or only mildly frail based on a medical check-up and two standard geriatric assessments (called G8 and miniCOG™), which measure overall health and thinking ability in older adults
  • People who have been diagnosed with prostate cancer within the last 6 months, where the cancer is either a high-grade type (Gleason grade 8–10, meaning a more aggressive form that is visible or able to be felt on examination) or a locally advanced type (meaning the cancer has grown beyond the prostate but has not spread to other parts of the body)
  • People who are able to read, understand, and complete health-related quality-of-life questionnaires
  • People who are male
  • People who are able to give their informed consent and follow the requirements of the trial

Who may not be able to join:

  • People living with dementia or those who are unable to give informed consent
  • People who have previously had radiation treatment to the pelvic area
  • People who have been on hormone therapy for more than 3 months before the point of joining the trial
  • People whose scans (MRI, CT, or PSMA-PET CT) show that the cancer has spread to the lymph nodes
  • People whose scans (MRI, CT, bone scan, or PSMA-PET CT) show that the cancer has spread to distant parts of the body
  • People who are significantly disabled or have serious other health conditions, as identified by the G8 health screening tool
  • People who are unable to read, understand, or complete health-related quality-of-life questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sven Loffeler, MD, PhD, The Hospital of Vestfold

Phone: +4792235628

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sven Löffeler
Registry
ClinicalTrials.gov
Start date
4 November 2022
Est. completion
31 December 2029

Where this trial is recruiting

🇩🇰 Denmark 🇫🇮 Finland 🇳🇴 Norway 🇸🇪 Sweden

Primary endpoints

Overall survival; Burden of disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov